Smriti Mandhana and Manika Batra becomes the brand ambassadors for Herbalife India's vritilife
Herbalife India
, a premier health and
wellness
company, community and platform, has announced the extension of its partnership with two of India's sports icons –
Smriti Mandhana
, Indian cricketer and
Manika Batra
, Indian table tennis player –for its
vritilife
Ayurvedic skin care
range.
This strategic partnership aims to address wellness through clinically tested
skincare routine
and reflects Herbalife's commitment to promoting well-being from the inside out.
As athletes who face high levels of physical and environmental stress, Mandhana and Batra understand the importance of conscious skincare that supports their active lifestyles without compromising on quality or authenticity.
This partnership reflects a shared vision in championing skincare — one that blends Ayurvedic tradition with modern science to empower every individual to feel confident in their own skin.
Ajay Khanna, managing director, Herbalife India, said, 'As we continue to expand this range, we are delighted that Smriti Mandhana and Manika Batra—already valued ambassadors for Herbalife—are extending their association to champion the vritilife skincare range. They embody the spirit of balance, strength, and authenticity—values that are integral to vritilife. Their inspiring journeys will help us encourage more people to embrace skincare as an empowering aspect of
holistic well-being
.'
vritilife's Ayurvedic skin care range currently includes a
Facial Cleanser
, Facial Toner, Facial Serum and Moisturiser. The skin care range stands out for its use of
botanicals
like Neem, Turmeric, Aloe Vera and Kumkumadi oil.
Mandhana, Indian cricketer said, 'I'm delighted to join vritilife family as their brand ambassador. As an athlete, taking care of my skin while constantly being on the move is essential, and vritilife's Ayurvedic-based formulations truly align with my lifestyle. I believe in promoting wellness, and vritilife reflects that ethos perfectly.'
Batra, Indian table tennis player said, "In sport and in life, discipline and self-care go hand in hand. With vritilife, I've found skincare that is deeply rooted in tradition, and yet refreshingly modern. I am happy to represent the brand and celebrate the diverse beauty traditions of this nation.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
3 hours ago
- Time of India
Health department will start siddha fertility clinic, says min Ma Su
Chennai: The health department will start fertility clinics under the department of Indian medicine on a pilot basis, similar to allopathic fertility clinics, at the Govt Siddha Hospital in Chennai, health minister Ma Subramanian said on Saturday. The minister, who took part in a yoga demonstration as part of International Yoga Day, said the state started three allopathic fertility clinics - one each in Chennai, Coimbatore, and Salem - recognizing the increasing prevalence of infertility and the need for improved access to affordable and high-quality fertility care, as well as further research into the underlying causes and effective prevention strategies. "I read an article by a doctor from this institution who said textbooks of siddha medicine, written centuries ago, prescribe drugs to solve infertility. We will soon start a siddha clinic for fertility on this campus," he said. The state is also working on legislation to set up a siddha university at Madhavaram. The Tamil Nadu Siddha Medical University Bill , 2022, which was tabled in the state legislative assembly, was earlier withdrawn. The govt said it will undertake fresh legislation in tune with the provisions contained in the National Commission for Indian System of Medicine Act. In 2021-2022, the govt announced it would establish a separate siddha university. A bill passed by the Tamil Nadu assembly on April 28, 2022, was sent for the Governor's assent, but it was sent from Raj Bhavan for the assent of the President. The Centre said certain provisions of the Tamil Nadu Siddha Medical University Bill, 2022, are not in accordance with the National Commission for Indian System of Medicine Act, 2020. "We will place the new bill in the coming assembly session," Subramanian said. Tamil Nadu is the only state where there are govt-run colleges for five streams of Indian medicine and homeopathy. The govt will fill doctor vacancies in this stream soon.
&w=3840&q=100)
Business Standard
4 hours ago
- Business Standard
Kashmik Formulation targets ₹100 crore revenue in FY26, eyes IPO
With a growing emphasis on affordable medicines and export-led growth, Ahmedabad-based Kashmik Formulation is targeting revenue of Rs 100 crore for FY26 — more than double its FY25 topline of Rs 40 crore. The company is planning to boost production capacity and invest in automation as it eyes new markets and future growth. Kashmik Formulation is also considering an initial public offering (IPO) within the next two to three years to scale its market presence and support future growth. While aiming to be a major player, it does not expect to become a top 20 or top 10 Indian contract manufacturer in the immediate term, considering it part of a longer-term plan. Founded in 2017, the company operates at full capacity with a daily output of 10 million tablets. Kashmik is now investing Rs 20 crore to ramp up capacity by 50 per cent to 15 million tablets per day. The company currently produces around 250 million units a month and is expanding its ground and first-floor production facilities to meet the rising demand. 'Our current clients include Cipla and Dr. Lal Pathlabs. At this point, our contract manufacturing capacity is fully utilised, but once the new capacity comes online, we will look to onboard more clients,' said Nilesh Patel, managing director. Branded generics account for nearly 70 per cent of Kashmik's revenue, with contract manufacturing contributing 20–30 per cent. The company is also stepping up its export focus, aiming to increase the share of exports from the current 20 per cent to 50 per cent over the next few years. Kashmik is in the process of registering its products in semi-regulated markets such as Africa, Myanmar, and Latin America. 'We're not targeting regulated markets yet, but we're actively working to expand in semi-regulated geographies. Registration is underway, and that will be a key driver for our export ambitions,' said Patel. To improve operational efficiency, Kashmik is also investing Rs 4–5 crore in packaging automation and AI-driven solutions. While the company is not yet investing heavily in research collaborations, it has plans to set up a new research and development centre in Jammu. A foray into injectables is also on the cards, with a new facility planned within the next 3–5 years. On the pricing front, Kashmik has launched Dapagliflozin, an anti-diabetic drug under its DAPNEC brand, which the company claims is priced approximately 400 per cent lower than competing brands. 'It's a highly competitive space, but we're targeting volume growth through affordability,' said Patel. Like many Indian pharma companies, Kashmik faces challenges in active pharmaceutical ingredient (API) sourcing, especially due to heavy dependence on China. 'Cost remains a major barrier to diversifying away from Chinese APIs. Any disruption in supply from China could hit production significantly,' Patel added. Despite headwinds, the company is optimistic about its growth trajectory.
Economic Times
5 hours ago
- Economic Times
Go on, pop the innovation pill: ₹5,000 cr push signals India's shift from copy to create
Stir things up Rollout of the ₹5,000-cr Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme signals a shift in how India approaches the sector's growth. This initiative, expected to begin disbursals by the end of 2025, could attract ₹17,000 cr in additional R&D investment. For an industry that has long been associated with generic manufacturing, this represents a paradigm shift towards innovation-led pharma world is approaching a 'patent cliff', and for Indian firms, it represents an unprecedented opportunity: 24 mega-selling drugs with combined annual sales exceeding $250 bn will lose patent protection by 2030. This means blockbuster medicines like Humira for rheumatoid arthritis, Keytruda for cancer treatment, Stelara for psoriasis, and Symbicort for asthma will soon be open for generic manufacturing. When these patents expire, drug prices fall by at least 50%. For a country where out-of-pocket (OoP) healthcare expenses are high, this holds immense significance alongside its commercial potential. Capturing these opportunities won't be easy. Indian firms will face tough competition from generics and must match the original drug standards. Success will hinge on investment in bioequivalence studies, regulatory compliance and resilient supply chains. Indian pharma companies are eyeing these opportunities. Zydus, Sun Pharma, and Bharat Serums and Vaccines (now part of Mankind Pharma) have invested in establishing world-class R&D centres, focusing on developing new chemical entities. The younger generation of scientists and entrepreneurs, bringing fresh perspectives, is accelerating the transition from a generic-focused industry to one that balances both generic excellence and innovative drug discovery. MNCs are also rethinking their view of the Indian market: Novartis, Novo Nordisk and Eli Lilly have chosen to out-license their brands to Indian firms rather than directly market them here. This trend reflects both the growing capabilities of domestic firms and the unique challenges of serving India's diverse and price-sensitive market. These partnerships benefit all. International companies can maintain a presence in India without the complexities of direct operations, while Indian firms gain access to established brands and molecules, leveraging deep market understanding and extensive distribution networks. However, building these relationships requires investment in compliance systems, quality infrastructure, and continuous capability upgrades to meet the exacting standards of international positives in the sector include: Exemption of 36 life-saving drugs from basic customs duty will benefit companies bringing in innovative medicines. Drugs like AstraZeneca's Selumetinib, Pfizer's Lorlatinib, Novartis' Ribociclib, and GSK's Mepolizumab will now be more affordable. Additionally, six more life-saving medicines have been added to the concessional 5% duty slab, primarily targeting cancer, rare diseases and other chronic conditions. The health budget has risen to over ₹95,000 cr for FY26, up 9.46%. More than a numbers game, it's about building a healthcare ecosystem fit for our vast population. 15,479 Jan Aushadhi Kendras provide generic medicines at prices up to 80% lower than branded equivalents. A heart medicine that once cost ₹500 is available for ₹100, bringing essential treatments within reach of ordinary citizens. Yet, ensuring consistent quality and maintaining reliable supply chains remain a challenge. Extension of PM Ayushman Yojana to people above 70 years creates a virtuous cycle - more people seeking treatment drives demand for medicines, which, in turn, encourages pharma companies to invest in better products and wider distribution. Development of healthcare infra in tier-2 and tier-3 cities is also helping. However, attracting and retaining qualified medical professionals in these locations remains a hurdle, requiring innovative approaches to compensation, career development and quality-of-life considerations. Again, the market for pharma products will, then, be able to expand. A 'nutraceutical revolution' is underway. With the market expected to grow from $4 bn in 2020 to $18 bn by December, nutraceuticals represent a significant growth avenue for companies willing to invest in quality and innovation. The convergence of multiple factors - patent opportunities, GoI support, infrastructure development and changing consumer behaviour - is creating unprecedented opportunities for the sector. Companies that embrace innovation, while maintaining traditional strengths in affordable healthcare delivery, will thrive. The writer is CEO, Mankind Pharma (Disclaimer: The opinions expressed in this column are that of the writer. The facts and opinions expressed here do not reflect the views of Elevate your knowledge and leadership skills at a cost cheaper than your daily tea. Second only to L&T, but controversies may weaken this infra powerhouse's growth story Looking for quick buck in unlisted shares? Better think twice! How Vedanta's Anil Agarwal bettered Warren Buffett in returns Rivers are moving more goods than before. But why aren't they making a splash yet? Stock Radar: Supreme Industries stock down by about 30%! Breakout from rounding bottom formation suggests bulls are catching up Two Trades for Today: A large-cap auto major for 6.7% gain, a mid-cap auto stock for almost 7% rise After a gap of 4 years, are HDFC, Axis, Kotak banks ready for re-rating? 5 bank stocks with upside potential of up to 35% For medium- to long-term investors with moderate risk appetite: 6 large-cap stocks with an upside potential of up to 40%
